Evidence map›Paper›PMID 37873934›Full record

ReviewJournal of labelled compounds & radiopharmaceuticals2023

Site-specifically radiolabeled nanobodies for imaging blood-brain barrier penetration and targeting in the brain.

Yingbo Li, Junfeng Wang

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of labelled compounds & radiopharmaceuticals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Yingbo LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Junfeng WangGordon Center for Medical Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5795-5719
Harvard University · USPeking University · CN

Funding

Development of PET imaging probes for metabolic glutamate receptor 3 (mGLuR3)K25AG061282 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI WANG, JUNFENG · 2019 to 2023
$754k
NIA NIH HHS K25 AG061282
6 · The paper itself

Abstract

Nanobodies (Nbs) hold significant potential in molecular imaging due to their unique characteristics. However, there are challenges to overcome when it comes to brain imaging. To address these obstacles, collaborative efforts and interdisciplinary research are needed. This article aims to raise awareness and encourage collaboration among researchers from various fields to find solutions for effective brain imaging using Nbs. By fostering cooperation and knowledge sharing, we can make progress in overcoming the existing limitations and pave the way for improved molecular imaging techniques in the future.

Indexed as

Single-Domain AntibodiesBlood-Brain BarrierMolecular ImagingSingle-Domain AntibodiesBBB penetrationbrain disordermolecular imagingnanobodysite-specific labeling

Identifiers

PMID37873934
PMCPMC10842159
OpenAlexW4387893938

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.